ArticleImmunoTargets and therapy2026
Multi-Omics Analysis Reveals m7G Methylation-Related Genes May Be Involved in TGF-β Signaling-Mediated Anti-PD-L1 Response in Bladder Cancer.
Article in ImmunoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunotherapy resistance is a significant challenge in bladder cancer treatment. The role of N7-methylguanosine (m7G) methylation in this process remains unclear. This study aims to investigate the potential role of m7G methylation-related genes (m7GRGs) in immunotherapy resistance using a multi-omics approach. Methods: This study integrated bioinformatics analysis with in vitro experimental validation. We obtained bulk, single-cell, and spatial transcriptomics data from multiple bladder cancer cohorts in public databases, including TCGA, GEO and IMvigor210. Machine learning models were performed to identify molecular clusters and screen signature genes. Gene ontology analysis was used for gene function enrichment. siRNA transfection knocked down the expression of characteristic genes in bladder cancer cell lines to validate their roles in signaling regulation. Gene expression was assessed using qRT-PCR, Western blot, and immunohistochemistry. Additionally, CCK-8 and wound healing assays were performed to evaluate the effects of characteristic genes on the proliferation and migration of bladder cancer cells. Results: Two bladder cancer molecular clusters were identified, with the C1 cluster exhibiting worse prognosis, higher m7GRGs expression, and an immunosuppressive microenvironment. NUDT10 was a key prognostic gene distinguishing molecular clusters. A subset of differentially methylated genes correlated with anti-PD-L1 resistance were enriched in the TGF-β signaling pathway. Single-cell and spatial transcriptomics revealed that NUDT10 was co-expressed with TGF-β activator LRRC32. IMvigor210 and GSE176307 datasets found that expression of NUDT10 and LRRC32 was associated with poor response to anti-PD-L1 therapy. Knockdown of NUDT10 in bladder cancer cells inhibited the expression of LRRC32 and reduced the proliferation and migration abilities of the cancer cells. Conclusion: This study identifies NUDT10 as a key gene associated with poor prognosis based on m7GRGs-defined molecular clusters in bladder cancer. NUDT10 expression may regulate TGF-β signaling and is associated with poor response to anti-PD-L1 therapy in advanced or metastatic bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.